Box selleckchem Bicalutamide 1: Article 14 of the FCTC��Demand reduction measures concerning tobacco dependence and cessation Each Party shall develop and disseminate appropriate, comprehensive, and integrated guidelines based on scientific evidence and best practices, taking into account national circumstances and priorities, and shall take effective measures to promote cessation of tobacco use and adequate treatment for tobacco dependence.

Toward this end, each Party shall endeavor to design and implement effective programs aimed at promoting the cessation of tobacco use, in such locations as educational institutions, health care facilities, workplaces, and sporting environments; include diagnosis and treatment of tobacco dependence and counseling services on cessation of tobacco use in national health and education programs, plans, and strategies, with the participation of health workers, community workers, and social workers as appropriate; establish in health care facilities and rehabilitation centers programs for diagnosing, counseling, preventing, and treating tobacco dependence; and collaborate with other Parties to facilitate accessibility and affordability for treatment of tobacco dependence including pharmaceutical products pursuant to Article 22. Such products and their constituents may include medicines, products used to administer medicines and diagnostics when appropriate. Source: WHO Framework Convention on Tobacco Control (2003). Retrieved from http://apps.who.int/iris/bitstream/10665/42811/1/9241591013.pdf (date last accessed December 4, 2012).

Reproduced with permission from the World Health Organization. GOAL OF ARTICLE 14 GUIDELINES Guidelines for the implementation of Article 14 of the FCTC were developed to guide Parties in meeting their obligations to Article 14 (WHO Guidelines for Implementation of Article 14 of the WHO Framework Convention on Tobacco Control, 2010) and were adopted at the fourth Conference of the Parties to the FCTC in November 2010 (Raw, 2011). The guidelines first outline underlying considerations in treating tobacco dependence and follow with recommendations regarding the (a) development of infrastructure to support tobacco cessation, (b) key components of a system to help tobacco users quit, (c) development of cessation support, and (d) monitoring and evaluation.

Many of the underlying considerations and recommendations in the guidelines are relevant to future research needs and so are listed in Box 2 for reference. Box 2: Summary of underlying consideration and key recommendations of the Article 14 guidelines Underlying considerations It is important to implement TDT measures synergistically with other Entinostat tobacco control measures. Tobacco cessation and TDT strategies should be based on the best available evidence of effectiveness. Treatment should be accessible and affordable.